25 XP   0   0   10

Lipigon Pharmaceuticals AB
Buy, Hold or Sell?

Let's analyse Lipigon together

PenkeI guess you are interested in Lipigon Pharmaceuticals AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lipigon Pharmaceuticals AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Lipigon Pharmaceuticals AB

I send you an email if I find something interesting about Lipigon Pharmaceuticals AB.

Quick analysis of Lipigon (30 sec.)










What can you expect buying and holding a share of Lipigon? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.22
Expected worth in 1 year
kr0.42
How sure are you?
31.3%

+ What do you gain per year?

Total Gains per Share
kr0.19
Return On Investment
51.6%

For what price can you sell your share?

Current Price per Share
kr0.38
Expected price per share
kr0.325 - kr0.43
How sure are you?
50%

1. Valuation of Lipigon (5 min.)




Live pricePrice per Share (EOD)

kr0.38

Intrinsic Value Per Share

kr-2.07 - kr-2.39

Total Value Per Share

kr-1.84 - kr-2.16

2. Growth of Lipigon (5 min.)




Is Lipigon growing?

Current yearPrevious yearGrowGrow %
How rich?$2.6m$1.1m$581.7k32.7%

How much money is Lipigon making?

Current yearPrevious yearGrowGrow %
Making money-$284.9k-$884.9k$599.9k210.5%
Net Profit Margin-329.8%-588.2%--

How much money comes from the company's main activities?

3. Financial Health of Lipigon (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#812 / 1031

Most Revenue
#562 / 1031

Most Profit
#189 / 1031

Most Efficient
#712 / 1031

What can you expect buying and holding a share of Lipigon? (5 min.)

Welcome investor! Lipigon's management wants to use your money to grow the business. In return you get a share of Lipigon.

What can you expect buying and holding a share of Lipigon?

First you should know what it really means to hold a share of Lipigon. And how you can make/lose money.

Speculation

The Price per Share of Lipigon is kr0.377. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lipigon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lipigon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.22. Based on the TTM, the Book Value Change Per Share is kr0.05 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lipigon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.01-1.5%0.000.1%-0.01-1.9%0.00-1.1%0.00-1.1%
Usd Book Value Change Per Share0.012.2%0.001.2%0.00-0.9%0.000.4%0.000.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.012.2%0.001.2%0.00-0.9%0.000.4%0.000.4%
Usd Price Per Share0.04-0.05-0.21-0.25-0.25-
Price to Earnings Ratio-1.80--0.36--7.87--9.68--9.68-
Price-to-Total Gains Ratio4.95--6.23--14.55--24.46--24.46-
Price to Book Ratio1.92--4.81-24.07-11.22-11.22-
Price-to-Total Gains Ratio4.95--6.23--14.55--24.46--24.46-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.035438
Number of shares28218
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (28218 shares)128.8937.30
Gains per Year (28218 shares)515.57149.20
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
105165060149139
20103110220298288
30154715380448437
40206220540597586
50257825700746735
60309330860895884
7036093602010441033
8041254118011941182
9046404634013431331
10051565150014921480

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.010.00.016.7%2.014.00.012.5%2.014.00.012.5%2.014.00.012.5%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%5.08.03.031.3%5.08.03.031.3%5.08.03.031.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.016.00.0%0.00.016.00.0%0.00.016.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%5.08.03.031.3%5.08.03.031.3%5.08.03.031.3%

Fundamentals of Lipigon

About Lipigon Pharmaceuticals AB

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden.

Fundamental data was last updated by Penke on 2024-03-10 17:14:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Lipigon Pharmaceuticals AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Lipigon earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Lipigon to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lipigon Pharmaceuticals AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-329.8%+329.8%
TTM-329.8%YOY-588.2%+258.4%
TTM-329.8%5Y-744.9%+415.1%
5Y-744.9%10Y-744.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM-329.8%-205.8%-124.0%
YOY-588.2%-262.1%-326.1%
5Y-744.9%-455.6%-289.3%
10Y-744.9%-589.0%-155.9%
1.1.2. Return on Assets

Shows how efficient Lipigon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lipigon to the Biotechnology industry mean.
  • -22.5% Return on Assets means that Lipigon generated kr-0.22 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lipigon Pharmaceuticals AB:

  • The MRQ is -22.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -40.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.5%TTM-40.9%+18.4%
TTM-40.9%YOY-53.1%+12.2%
TTM-40.9%5Y-32.0%-8.9%
5Y-32.0%10Y-32.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.5%-12.5%-10.0%
TTM-40.9%-12.2%-28.7%
YOY-53.1%-11.2%-41.9%
5Y-32.0%-13.4%-18.6%
10Y-32.0%-14.7%-17.3%
1.1.3. Return on Equity

Shows how efficient Lipigon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lipigon to the Biotechnology industry mean.
  • -26.6% Return on Equity means Lipigon generated kr-0.27 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lipigon Pharmaceuticals AB:

  • The MRQ is -26.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -5.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-26.6%TTM-5.5%-21.0%
TTM-5.5%YOY-104.2%+98.6%
TTM-5.5%5Y-37.4%+31.9%
5Y-37.4%10Y-37.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.6%-15.8%-10.8%
TTM-5.5%-15.7%+10.2%
YOY-104.2%-13.9%-90.3%
5Y-37.4%-18.3%-19.1%
10Y-37.4%-19.2%-18.2%

1.2. Operating Efficiency of Lipigon Pharmaceuticals AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Lipigon is operating .

  • Measures how much profit Lipigon makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lipigon to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lipigon Pharmaceuticals AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-329.7%+329.7%
TTM-329.7%YOY-590.8%+261.1%
TTM-329.7%5Y-712.7%+383.0%
5Y-712.7%10Y-712.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM-329.7%-210.1%-119.6%
YOY-590.8%-279.7%-311.1%
5Y-712.7%-459.9%-252.8%
10Y-712.7%-596.9%-115.8%
1.2.2. Operating Ratio

Measures how efficient Lipigon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Lipigon Pharmaceuticals AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM7.970-7.970
TTM7.970YOY6.162+1.809
TTM7.9705Y9.184-1.214
5Y9.18410Y9.1840.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM7.9703.193+4.777
YOY6.1623.615+2.547
5Y9.1845.560+3.624
10Y9.1847.396+1.788

1.3. Liquidity of Lipigon Pharmaceuticals AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Lipigon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.51 means the company has kr6.51 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Lipigon Pharmaceuticals AB:

  • The MRQ is 6.505. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.560. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.505TTM4.560+1.945
TTM4.560YOY2.626+1.934
TTM4.5605Y5.393-0.833
5Y5.39310Y5.3930.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5053.986+2.519
TTM4.5604.440+0.120
YOY2.6265.552-2.926
5Y5.3936.158-0.765
10Y5.3936.492-1.099
1.3.2. Quick Ratio

Measures if Lipigon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lipigon to the Biotechnology industry mean.
  • A Quick Ratio of 6.51 means the company can pay off kr6.51 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lipigon Pharmaceuticals AB:

  • The MRQ is 6.505. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.560. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.505TTM4.560+1.945
TTM4.560YOY2.332+2.228
TTM4.5605Y5.222-0.662
5Y5.22210Y5.2220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.5053.638+2.867
TTM4.5604.168+0.392
YOY2.3325.515-3.183
5Y5.2226.012-0.790
10Y5.2226.209-0.987

1.4. Solvency of Lipigon Pharmaceuticals AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Lipigon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lipigon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Lipigon assets are financed with 15.4% credit (debt) and the remaining percentage (100% - 15.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lipigon Pharmaceuticals AB:

  • The MRQ is 0.154. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.536. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.154TTM0.536-0.382
TTM0.536YOY0.375+0.161
TTM0.5365Y0.264+0.271
5Y0.26410Y0.2640.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1540.335-0.181
TTM0.5360.330+0.206
YOY0.3750.267+0.108
5Y0.2640.367-0.103
10Y0.2640.378-0.114
1.4.2. Debt to Equity Ratio

Measures if Lipigon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lipigon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.1% means that company has kr0.18 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lipigon Pharmaceuticals AB:

  • The MRQ is 0.181. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.159. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.181TTM0.159+0.022
TTM0.159YOY0.757-0.598
TTM0.1595Y0.272-0.113
5Y0.27210Y0.2720.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1810.376-0.195
TTM0.1590.398-0.239
YOY0.7570.334+0.423
5Y0.2720.429-0.157
10Y0.2720.476-0.204

2. Market Valuation of Lipigon Pharmaceuticals AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Lipigon generates.

  • Above 15 is considered overpriced but always compare Lipigon to the Biotechnology industry mean.
  • A PE ratio of -1.80 means the investor is paying kr-1.80 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lipigon Pharmaceuticals AB:

  • The EOD is -1.577. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.803. Based on the earnings, the company is expensive. -2
  • The TTM is -0.356. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.577MRQ-1.803+0.226
MRQ-1.803TTM-0.356-1.447
TTM-0.356YOY-7.874+7.518
TTM-0.3565Y-9.681+9.325
5Y-9.68110Y-9.6810.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.577-2.643+1.066
MRQ-1.803-2.418+0.615
TTM-0.356-2.742+2.386
YOY-7.874-4.123-3.751
5Y-9.681-6.257-3.424
10Y-9.681-6.478-3.203
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lipigon Pharmaceuticals AB:

  • The EOD is -1.839. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.102. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.147. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.839MRQ-2.102+0.263
MRQ-2.102TTM-1.147-0.955
TTM-1.147YOY-7.317+6.170
TTM-1.1475Y-10.169+9.022
5Y-10.16910Y-10.1690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.839-3.244+1.405
MRQ-2.102-2.939+0.837
TTM-1.147-3.478+2.331
YOY-7.317-5.592-1.725
5Y-10.169-8.473-1.696
10Y-10.169-8.881-1.288
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Lipigon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.92 means the investor is paying kr1.92 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Lipigon Pharmaceuticals AB:

  • The EOD is 1.676. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.916. Based on the equity, the company is underpriced. +1
  • The TTM is -4.806. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.676MRQ1.916-0.240
MRQ1.916TTM-4.806+6.721
TTM-4.806YOY24.075-28.881
TTM-4.8065Y11.224-16.029
5Y11.22410Y11.2240.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.6762.124-0.448
MRQ1.9162.041-0.125
TTM-4.8062.118-6.924
YOY24.0752.915+21.160
5Y11.2243.682+7.542
10Y11.2244.114+7.110
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Lipigon Pharmaceuticals AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0870.049+79%-0.038+143%0.014+520%0.014+520%
Book Value Per Share--0.2250.127+78%0.101+123%0.147+54%0.147+54%
Current Ratio--6.5054.560+43%2.626+148%5.393+21%5.393+21%
Debt To Asset Ratio--0.1540.536-71%0.375-59%0.264-42%0.264-42%
Debt To Equity Ratio--0.1810.159+14%0.757-76%0.272-33%0.272-33%
Dividend Per Share----0%-0%-0%-0%
Eps---0.0600.003-2400%-0.075+25%-0.042-29%-0.042-29%
Free Cash Flow Per Share---0.051-0.027-47%-0.074+44%-0.047-9%-0.047-9%
Free Cash Flow To Equity Per Share--0.0540.081-34%0.083-35%0.071-24%0.071-24%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---2.389--------
Intrinsic Value_10Y_min---2.066--------
Intrinsic Value_1Y_max---0.231--------
Intrinsic Value_1Y_min---0.227--------
Intrinsic Value_3Y_max---0.700--------
Intrinsic Value_3Y_min---0.668--------
Intrinsic Value_5Y_max---1.177--------
Intrinsic Value_5Y_min---1.092--------
Market Cap47661094.000-14%54487882.00076263424.655-29%288874270.000-81%341441956.164-84%341441956.164-84%
Net Profit Margin----3.2980%-5.8820%-7.4490%-7.4490%
Operating Margin----3.2970%-5.9080%-7.1270%-7.1270%
Operating Ratio---7.970-100%6.162-100%9.184-100%9.184-100%
Pb Ratio1.676-14%1.916-4.806+351%24.075-92%11.224-83%11.224-83%
Pe Ratio-1.577+13%-1.803-0.356-80%-7.874+337%-9.681+437%-9.681+437%
Price Per Share0.377-14%0.4310.526-18%2.285-81%2.682-84%2.682-84%
Price To Free Cash Flow Ratio-1.839+13%-2.102-1.147-45%-7.317+248%-10.169+384%-10.169+384%
Price To Total Gains Ratio4.326-14%4.945-6.231+226%-14.548+394%-24.456+595%-24.456+595%
Quick Ratio--6.5054.560+43%2.332+179%5.222+25%5.222+25%
Return On Assets---0.225-0.409+82%-0.531+136%-0.320+42%-0.320+42%
Return On Equity---0.266-0.055-79%-1.042+292%-0.374+41%-0.374+41%
Total Gains Per Share--0.0870.049+79%-0.038+143%0.014+520%0.014+520%
Usd Book Value--2673736.0001781018.000+50%1199275.500+123%1810398.875+48%1810398.875+48%
Usd Book Value Change Per Share--0.0080.005+79%-0.004+143%0.001+520%0.001+520%
Usd Book Value Per Share--0.0210.012+78%0.009+123%0.014+54%0.014+54%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.0060.000-2400%-0.007+25%-0.004-29%-0.004-29%
Usd Free Cash Flow---609120.000-336496.500-45%-877772.000+44%-559728.875-8%-559728.875-8%
Usd Free Cash Flow Per Share---0.005-0.003-47%-0.007+44%-0.004-9%-0.004-9%
Usd Free Cash Flow To Equity Per Share--0.0050.008-34%0.008-35%0.007-24%0.007-24%
Usd Market Cap4480142.836-14%5121860.9087168761.918-29%27154181.380-81%32095543.879-84%32095543.879-84%
Usd Price Per Share0.035-14%0.0410.049-18%0.215-81%0.252-84%0.252-84%
Usd Profit---710264.000-284984.500-60%-884916.000+25%-581319.500-18%-581319.500-18%
Usd Revenue---385564.500-100%9165.000-100%137187.125-100%137187.125-100%
Usd Total Gains Per Share--0.0080.005+79%-0.004+143%0.001+520%0.001+520%
 EOD+2 -6MRQTTM+16 -15YOY+23 -85Y+17 -1410Y+17 -14

3.2. Fundamental Score

Let's check the fundamental score of Lipigon Pharmaceuticals AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.577
Price to Book Ratio (EOD)Between0-11.676
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.505
Current Ratio (MRQ)Greater than16.505
Debt to Asset Ratio (MRQ)Less than10.154
Debt to Equity Ratio (MRQ)Less than10.181
Return on Equity (MRQ)Greater than0.15-0.266
Return on Assets (MRQ)Greater than0.05-0.225
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Lipigon Pharmaceuticals AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.855
Ma 20Greater thanMa 500.381
Ma 50Greater thanMa 1000.427
Ma 100Greater thanMa 2000.432
OpenGreater thanClose0.380
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets33,602
Total Liabilities5,158
Total Stockholder Equity28,445
 As reported
Total Liabilities 5,158
Total Stockholder Equity+ 28,445
Total Assets = 33,602

Assets

Total Assets33,602
Total Current Assets33,553
Long-term Assets49
Total Current Assets
Cash And Cash Equivalents 31,927
Net Receivables 1,626
Total Current Assets  (as reported)33,553
Total Current Assets  (calculated)33,553
+/- 0
Long-term Assets
Property Plant Equipment 49
Long-term Assets Other 0
Long-term Assets  (as reported)49
Long-term Assets  (calculated)49
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,158
Long-term Liabilities0
Total Stockholder Equity28,445
Total Current Liabilities
Accounts payable 2,433
Other Current Liabilities 2,725
Total Current Liabilities  (as reported)5,158
Total Current Liabilities  (calculated)5,158
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock14,246
Retained Earnings -113,355
Other Stockholders Equity 127,554
Total Stockholder Equity (as reported)28,445
Total Stockholder Equity (calculated)28,445
+/-0
Other
Cash and Short Term Investments 31,927
Common Stock Shares Outstanding 85,688
Liabilities and Stockholders Equity 33,602
Net Debt -31,927
Net Working Capital 28,395



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
15,242
61,801
53,244
41,245
29,428
19,028
31,879
16,833
10,816
4,772
35,118
26,863
33,602
33,60226,86335,1184,77210,81616,83331,87919,02829,42841,24553,24461,80115,242000
   > Total Current Assets 
0
0
0
15,242
61,682
53,125
41,126
29,332
18,932
9,195
16,755
10,744
4,705
35,057
26,809
33,553
33,55326,80935,0574,70510,74416,7559,19518,93229,33241,12653,12561,68215,242000
       Cash And Cash Equivalents 
0
0
0
12,551
58,945
50,170
39,645
28,467
16,702
3,719
15,576
9,637
4,272
17,309
25,218
31,927
31,92725,21817,3094,2729,63715,5763,71916,70228,46739,64550,17058,94512,551000
       Net Receivables 
0
0
0
759
1,977
1,993
1,135
103
103
103
103
1,014
433
17,749
1,590
1,626
1,6261,59017,7494331,0141031031031031,1351,9931,977759000
       Other Current Assets 
0
0
0
2,691
2,737
2,955
1,481
865
2,230
5,476
1,076
93
433
-1
1
0
01-1433931,0765,4762,2308651,4812,9552,7372,691000
   > Long-term Assets 
0
0
0
0
119
119
119
96
96
22,684
78
72
67
61
55
49
49556167727822,68496961191191190000
       Property Plant Equipment 
0
0
0
0
119
119
119
96
96
84
78
72
67
61
55
49
4955616772788496961191191190000
       Other Assets 
0
0
0
0
0
0
0
0
0
22,600
0
0
0
0
-1
0
0-1000022,600000000000
> Total Liabilities 
0
0
0
2,259
2,611
4,429
3,863
6,466
5,082
11,730
3,766
6,945
7,737
7,529
4,143
5,158
5,1584,1437,5297,7376,9453,76611,7305,0826,4663,8634,4292,6112,259000
   > Total Current Liabilities 
0
0
0
2,259
2,611
4,429
3,863
6,466
5,082
11,730
3,766
6,945
7,737
7,529
4,143
5,158
5,1584,1437,5297,7376,9453,76611,7305,0826,4663,8634,4292,6112,259000
       Accounts payable 
0
0
0
1,113
1,164
2,865
2,952
5,292
3,803
5,230
2,628
3,487
2,494
1,618
1,445
2,433
2,4331,4451,6182,4943,4872,6285,2303,8035,2922,9522,8651,1641,113000
       Other Current Liabilities 
0
0
0
1,146
1,447
1,564
911
1,174
1,279
6,500
1,138
3,458
5,243
5,911
2,698
2,725
2,7252,6985,9115,2433,4581,1386,5001,2791,1749111,5641,4471,146000
   > Long-term Liabilities 
0
0
0
0
0
0
0
5,292
3,803
5,230
2,628
3,487
0
0
0
0
00003,4872,6285,2303,8035,2920000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0010000000000000
> Total Stockholder Equity
0
0
0
12,983
59,190
48,815
37,382
22,962
13,946
20,149
13,067
3,871
-2,965
27,589
22,720
28,445
28,44522,72027,589-2,9653,87113,06720,14913,94622,96237,38248,81559,19012,983000
   Common Stock
0
0
0
533
1,097
1,097
1,097
1,097
1,097
1,097
2,281
2,281
2,281
9,017
9,017
14,246
14,2469,0179,0172,2812,2812,2811,0971,0971,0971,0971,0971,097533000
   Retained Earnings Total Equity0000000000000000
   Accumulated Other Comprehensive Income 0000000000000000
   Capital Surplus 0000000000000000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
34,859
85,387
85,387
85,387
85,387
85,387
104,239
102,817
102,817
102,817
119,502
119,502
127,554
127,554119,502119,502102,817102,817102,817104,23985,38785,38785,38785,38785,38734,859000



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue16,407
Cost of Revenue-28,984
Gross Profit-12,577-12,577
 
Operating Income (+$)
Gross Profit-12,577
Operating Expense-30,591
Operating Income-12,577-43,168
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense30,5910
 
Net Interest Income (+$)
Interest Income28
Interest Expense-3
Other Finance Cost-1
Net Interest Income26
 
Pretax Income (+$)
Operating Income-12,577
Net Interest Income26
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-12,128-13,026
EBIT - interestExpense = -12,580
-12,128
-12,125
Interest Expense3
Earnings Before Interest and Taxes (EBIT)-12,577-12,125
Earnings Before Interest and Taxes (EBITDA)-12,553
 
After tax Income (+$)
Income Before Tax-12,128
Tax Provision-0
Net Income From Continuing Ops-13,768-12,128
Net Income-12,128
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses28,984
Total Other Income/Expenses Net449-26
 

Technical Analysis of Lipigon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lipigon. The general trend of Lipigon is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lipigon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lipigon Pharmaceuticals AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.386 < 0.43 < 0.43.

The bearish price targets are: 0.351 > 0.333 > 0.325.

Tweet this
Lipigon Pharmaceuticals AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lipigon Pharmaceuticals AB. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lipigon Pharmaceuticals AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lipigon Pharmaceuticals AB. The current macd is -0.01295714.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lipigon price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Lipigon. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Lipigon price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Lipigon Pharmaceuticals AB Daily Moving Average Convergence/Divergence (MACD) ChartLipigon Pharmaceuticals AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lipigon Pharmaceuticals AB. The current adx is 17.83.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Lipigon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Lipigon Pharmaceuticals AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lipigon Pharmaceuticals AB. The current sar is 0.42165929.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Lipigon Pharmaceuticals AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lipigon Pharmaceuticals AB. The current rsi is 43.86. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Lipigon Pharmaceuticals AB Daily Relative Strength Index (RSI) ChartLipigon Pharmaceuticals AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lipigon Pharmaceuticals AB. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lipigon price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Lipigon Pharmaceuticals AB Daily Stochastic Oscillator ChartLipigon Pharmaceuticals AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lipigon Pharmaceuticals AB. The current cci is -27.7037037.

Lipigon Pharmaceuticals AB Daily Commodity Channel Index (CCI) ChartLipigon Pharmaceuticals AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lipigon Pharmaceuticals AB. The current cmo is -7.66843695.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Lipigon Pharmaceuticals AB Daily Chande Momentum Oscillator (CMO) ChartLipigon Pharmaceuticals AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lipigon Pharmaceuticals AB. The current willr is -48.23529412.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Lipigon is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Lipigon Pharmaceuticals AB Daily Williams %R ChartLipigon Pharmaceuticals AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lipigon Pharmaceuticals AB.

Lipigon Pharmaceuticals AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lipigon Pharmaceuticals AB. The current atr is 0.03466514.

Lipigon Pharmaceuticals AB Daily Average True Range (ATR) ChartLipigon Pharmaceuticals AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lipigon Pharmaceuticals AB. The current obv is 13,957,547.

Lipigon Pharmaceuticals AB Daily On-Balance Volume (OBV) ChartLipigon Pharmaceuticals AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lipigon Pharmaceuticals AB. The current mfi is 40.75.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Lipigon Pharmaceuticals AB Daily Money Flow Index (MFI) ChartLipigon Pharmaceuticals AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lipigon Pharmaceuticals AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Lipigon Pharmaceuticals AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lipigon Pharmaceuticals AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.855
Ma 20Greater thanMa 500.381
Ma 50Greater thanMa 1000.427
Ma 100Greater thanMa 2000.432
OpenGreater thanClose0.380
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Lipigon with someone you think should read this too:
  • Are you bullish or bearish on Lipigon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lipigon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lipigon Pharmaceuticals AB

I send you an email if I find something interesting about Lipigon Pharmaceuticals AB.


Comments

How you think about this?

Leave a comment

Stay informed about Lipigon Pharmaceuticals AB.

Receive notifications about Lipigon Pharmaceuticals AB in your mailbox!